MyTomorrows Files IPO Prospectus After Raising Tens of Millions in Funding to Advance Clinical Trial Matching Platform
What is the current state of processing and mining medical big data, and how will it evolve in the future? VCBeat (WeChat: vcbeat) will publish a series of reports on the global medical big data sector, covering typical case studies, investment and financing activities, and industry landscape developments, to serve as a reference for investors, entrepreneurs, and healthcare institutions.
MyTomorrows is a company that provides medical big data integration services to patients and physicians who require assistance during the diagnostic testing and drug development processes. Having expanded its reach to 16 countries across Europe and South America, the ambitious company is now preparing to enter the U.S. market.
As a startup, MyTomorrows’ internet platform provides accurate, cutting-edge public information, along with data on clinical trials and diagnostic tests, to enhance trend-based decision-making. This facilitates more rational and effective pharmacotherapy, while also helping patients with serious illnesses gain access to investigational drugs in clinical trials and advanced medical programs.
MyTomorrows, founded in 2012 and headquartered in Amsterdam, announced in September this year the opening of its API for accessing its database of clinical trial information on investigational drugs, as part of its market expansion strategy. Through this API, users can access more than 300,000 trial records. Prior to this launch, physicians and patients had to obtain such data exclusively through the MyTomorrows website. MyTomorrows believes that both patients and physicians stand to benefit from API access, as it enables them to retrieve and leverage these data within their existing workflows and environments.
What are the benefits of such a bold, open API interface? Users can search, filter, and download historical datasets from the entire clinical trial registry through this interface. The data is primarily sourced from the official website of the World Health Organization. Furthermore, the API is free to use and does not require registration. Users can search for treatments, match patients with relevant clinical trials, and expand their projects. This network was established to facilitate information exchange and collaborative efforts in identifying the most suitable clinical trial protocols.
Ronald Brus, Founder and CEO of MyTomorrows
Ronald Brus, Founder and CEO of MyTomorrows, stated in a press release: “We aim to further expand the application’s reach, enabling our data to better serve the needs of global healthcare systems and advance drug development.”
ForFor patients and doctors in needMyTomorrows provides a channel for accessing information, bringing greater transparency to experimental treatments for patients. Meanwhile, it also facilitates the provision and collection of better data, such as informing patients about how many individuals have received such treatments to date and what responses have been observed.
ForFor biotechnology companies,, abundant data and information resources can help them develop rational clinical trial protocols, accelerate the pace of new drug development, and thereby reduce the costs of new therapies. Meanwhile, this approach encourages healthy competition within the biotechnology industry.
Brus’s entrepreneurial idea stemmed from his father’s diagnosis with lung cancer. As a physician, Brus was well-versed in the European pharmaceutical and biotechnology industries. He quickly identified a drug with the potential to cure cancer, but six months passed without receiving the necessary regulatory approvals for its commercial sale. By the time approval was imminent, his father had already passed away. He remarked, “Some drugs may take three to eight years to reach the market, but most patients do not live long enough to benefit from them.”
Typically, the vast majority of requests in the early stages of drug trials are easily approved; however, obtaining approval for human clinical trials often takes more than a decade. In addition to testing for safety and side effects, therapeutic efficacy is also reviewed, and some drugs that have shown efficacy in animals fail the review process for unexplained reasons. Opaque regulations and policies further make the clinical application of drugs seem like a distant prospect.
The company spent three years reviewing relevant legislation in every European country. It established an automated system to handle all big data-related documentation, providing a one-stop service for patients and biotechnology and pharmaceutical companies. MyTomorrows negotiates directly with drug developers, documents risks and efficacy outcomes, and subsequently compiles relevant big data on the medications used to identify promising treatment options and streamline application filings. By focusing on the complex and time-consuming approval processes of health insurance regulatory authorities, it significantly reduces the time enterprises take to obtain approvals.
Meanwhile, MyTomorrows has also created an Amazon-like two-sided market, providing a navigation system for patients and physicians in need, through which they can access information on relevant clinical trials.
Both the FDA and the European EMA allow companies to administer drugs in early stages of development to patients with terminal illnesses. This practice is highly unethical, and many patients who genuinely need such treatments often fail to gain access. MyTomorrows helps pharmaceutical companies recruit a larger pool of volunteers, thereby enabling the selection of more suitable patients. If a patient is ineligible for enrollment in a clinical trial, MyTomorrows will register them on an Early Access Interest Form.
To date, MyTomorrows has secured tens of millions in cumulative financing and helped tens of thousands of patients gain access to clinical trials. The conditions addressed through its facilitated programs include acute lymphoblastic leukemia, T-cell lymphoma, and others. Following its success in the European market, Brus aims to make a significant impact in the U.S. market as well. “We all recognize the substantial demand in the U.S. market,” he stated. “We plan to launch our initiatives by the end of this year or in the first quarter of next year.”
Series Report:
[Medical Big Data] $30 Billion in Sales! SHYFT Analytics Is Expanding Aggressively
[Medical Big Data] Zephyr Health: Market Insight Consultant for Pharmaceutical Companies